Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice

@article{Bckryd2018DoTP,
  title={Do the potential benefits outweigh the risks? An update on the use of ziconotide in clinical practice},
  author={E. B{\"a}ckryd},
  journal={European Journal of Pain},
  year={2018},
  volume={22}
}
  • E. Bäckryd
  • Published 2018
  • Medicine
  • European Journal of Pain
  • Ziconotide is a selective and potent blocker of N‐type voltage‐gated calcium channels. It was approved by the Food and Drug Administration in 2004 and by the European Medicines Agency in 2005 for the treatment of severe chronic pain in patients needing intrathecal analgesia (ITA). The aim of this paper is to provide a practitioner‐oriented, educational, narrative, up‐to‐date review on the use of ziconotide in clinical pain medicine. Of special concern regarding safety is the partial incongruity… CONTINUE READING
    10 Citations

    Topics from this paper.

    Intrathecal therapy for pain in cancer patients
    • D. Dupoiron
    • Medicine
    • Current opinion in supportive and palliative care
    • 2019
    • 3
    Managing Chronic Non-Malignant Pain in the Elderly: Intrathecal Therapy
    • 3
    • PDF
    Pharmakologie der Nichtopioidanalgetika
    • 1
    Neurobiological activity of conotoxins via sodium channel modulation.

    References

    SHOWING 1-10 OF 103 REFERENCES
    Ziconotide: a clinical update and pharmacologic review
    • 88
    The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain
    • 9
    • PDF
    Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
    • 65
    • Highly Influential
    • PDF
    Ziconotide for treatment of severe chronic pain
    • 236
    • Highly Influential
    • PDF
    Acute cardiovascular toxicity of low-dose intrathecal ziconotide.
    • 5
    • PDF
    Intrathecal Ziconotide for Severe Chronic Pain: Safety and Tolerability Results of an Open-Label, Long-Term Trial
    • 94
    Intrathecal Therapy: What Has Changed With the Introduction of Ziconotide
    • 46